ConvaTec Group Logo
GB00BD3VFW73
A2AUD3
CTEC.L

ConvaTec Group

Loading quotes...

Forecast

There is no analyst data available for this company.


  • Convatec holds more than 5% of voting rights in own shares

    On 6 August 2026 Convatec exceeded the threshold of 5% of voting rights in the form of its own shares for the first time. As of 17 August the company held 102,469,942 own ordinary shares, representing 5.26% of the voting rights, acquired via Morgan Stanley as part of a repurchase programme of up to USD 200 million. The notification was made under the FCA’s disclosure and transparency rules and was published within the required deadline. » More on de.investing.com


  • ConvaTec confirms full-year guidance after solid H1 growth

    ConvaTec reports organic sales growth of 5% in the first half of 2026 excluding InnovaMatrix, an operating margin of 21.2% and EPS growth of 6%. Management reiterates the 2026 guidance, expecting an operating margin of at least 23% and double-digit EPS growth, and forecasts a stronger second half mainly thanks to Infusion Care and product launches. The company announces a £200m share buyback and a 15% increase in the interim dividend, while InnovaMatrix remains a drag and net debt stands at 2.3x EBITDA. ConvaTec plans increased investment in Infusion Care capacity (£90m in H1) and sees mid‑term organic growth of 6–8% per year. » More on de.investing.com


  • Convatec launches share buyback program of up to $200 million

    Convatec has announced a buyback program of up to $200 million, to be completed by no later than December 31, 2026. Morgan Stanley has been appointed to execute the program; up to 195,485,202 ordinary shares may be repurchased. The purpose is to reduce share capital and to meet obligations arising from employee stock options. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, ConvaTec Group has already paid €0.0642 in dividends. The last payout was in September.

Financials

In the last quarter, ConvaTec Group had revenue of €1.07bn and net profit of €46.93m
(EUR) June 2026
YoY
Revenue 1.07bn -
Gross profit 581.38m -
Net profit 46.93m -
EBITDA 252.89m -

Fundamentals

Metric Value
Market capitalization
€5.63bn
Number of shares
1.91bn
52-week high/low
€3.11 - €2.31
Dividend yield
2.17%
Dividends TTM
€0.0643
Beta
0.77
P/E ratio
51.91
PEG ratio
-1.23
P/B ratio
4.48
P/S ratio
2.53

Company profile

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Name
ConvaTec Group
CEO
Jonathan Peter Mason
Headquarters London, gl
United Kingdom
Website
IPO
26/10/2016
Employees 10,910

Ticker symbols

Exchange Symbol
London Stock Exchange
CTEC.L
Pnk
CNVVF
Frankfurt
2CV.F
Düsseldorf
2CV.DU
London
CTEC.L
SIX
2CV.SW
München
2CV.MU
🍪

Parqet  uses cookies. Learn more